Can breast cancer patients use soyafoods to help reduce risk of CHD?

British Journal of Nutrition

Volumn 108, Issue 5, 2012, Pages 810-819

  Messina, Mark ^a,b   Messina, Virginia ^a   Jenkins, David J A ^c  

^a LOMA LINDA UNIVERSITY   (United States)

^b Nutrition Matters Inc   (United States)

^c ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Breast cancer; Heart disease; Isoflavones; Phyto oestrogens; Soya

Indexed keywords

DAIDZEIN; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GENISTEIN; GLYCITEIN; ISOFLAVONE; LINOLEIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SOYBEAN PROTEIN; ANTINEOPLASTIC AGENT;

ARTERIAL WALL THICKNESS; BLOOD PRESSURE REGULATION; BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CARDIOVASCULAR RISK; DIET SUPPLEMENTATION; DISEASE FREE SURVIVAL; FOOD INTAKE; HUMAN; ISCHEMIC HEART DISEASE; NONHUMAN; NUTRITIONAL ASSESSMENT; NUTRITIONAL VALUE; POSTMENOPAUSE; PROTEIN INTAKE; RECURRENCE RISK; REVIEW; RISK REDUCTION; SOYBEAN; BLOOD; BREAST TUMOR; CORONARY ARTERY DISEASE; DIET THERAPY; FEMALE; RISK FACTOR;

ANTICARCINOGENIC AGENTS; BREAST NEOPLASMS; CHOLESTEROL, LDL; CORONARY DISEASE; FEMALE; HUMANS; RISK FACTORS; SOYBEANS;

EID: 84871871963     PISSN: 00071145     EISSN: 14752662     Source Type: Journal    
DOI: 10.1017/S0007114512001900     Document Type: Review

References (131)

1. Rand WM, Pellett PL & Young VR (2003) Meta-analysis of nitrogen balance studies for estimating protein requirements in healthy adults. Am J Clin Nutr 77, 109-127.
2. Hughes GJ, Ryan DJ, Mukherjea R, et al. (2011) Protein digestibility-corrected amino acid scores (PDCAAS) for soy protein isolates and concentrate: criteria for evaluation. J Agric Food Chem 59, 12707-12712.
3. Wu Z, Rodgers RP & Marshall AG (2004) Characterization of vegetable oils: detailed compositional fingerprints derived from electrospray ionization fourier transform ion cyclotron resonance mass spectrometry. J Agric Food Chem 52, 5322-5328.
4. Wu AH, Yu MC, Tseng CC, et al. (2008) Epidemiology of soy exposures and breast cancer risk. Br J Cancer 98, 9-14.
5. Yan L & Spitznagel EL (2009) Soy consumption and prostate cancer risk in men: a revisit of a meta-analysis. Am J Clin Nutr 89, 1155-1163.
6. Jenkins DJ, Mirrahimi A, Srichaikul K, et al. (2010) Soy protein reduces serum cholesterol by both intrinsic and food displacement mechanisms. J Nutr 140, 2302S-2311S.
7. Koh WP, Wu AH, Wang R, et al. (2009) Gender-specific associations between soy and risk of hip fracture in the Singapore Chinese Health Study. Am J Epidemiol 170, 901-909.
8. Zhang X, Shu XO, Li H, et al. (2005) Prospective cohort study of soy food consumption and risk of bone fracture among postmenopausal women. Arch Intern Med 165, 1890-1895.
9. Messina M & Hilakivi-Clarke L (2009) Early intake appears to be the key to the proposed protective effects of soy intake against breast cancer. Nutr Cancer 61, 792-798.
10. Messina M & Wu AH (2009) Perspectives on the soy-breast cancer relation. Am J Clin Nutr 89, 1673S-1679S.
11. Kokubo Y, Iso H, Ishihara J, et al. (2007) Association of dietary intake of soy, beans, and isoflavones with risk of cerebral and myocardial infarctions in Japanese populations: the Japan Public Health Center-based (JPHC) study cohort I. Circulation 116, 2553-2562.
12. Zhang B, Chen YM, Huang LL, et al. (2008) Greater habitual soyfood consumption is associated with decreased carotid intima-media thickness and better plasma lipids in Chinese middle-aged adults. Atherosclerosis 198, 403-411.
13. Anonymous (1999) Food labeling: health claims; soy protein and coronary heart disease. Food and Drug Administration, HHS. Final rule. Fed Regist 64, 57700-57733.
14. Dong JY, Tong X, Wu ZW, et al. (2011) Effect of soya protein on blood pressure: a meta-analysis of randomised controlled trials. Br J Nutr 106, 317-326.
15. Li SH, Liu XX, Bai YY, et al. (2010) Effect of oral isoflavone supplementation on vascular endothelial function in postmenopausal women: a meta-analysis of randomized placebo-controlled trials. Am J Clin Nutr 91, 480-486.
16. Balk E, Chung M, Chew P, et al. (2005) Effects of soy on health outcomes. Evid Rep Technol Assess (Summ) 126, 1-8.
17. Sacks FM, Lichtenstein A, Van Horn L, et al. (2006) Soy protein, isoflavones, and cardiovascular health: an American Heart Association Science Advisory for professionals from the Nutrition Committee. Circulation 113, 1034-1044.
18. Sirtori CR (2001) Risks and benefits of soy phytoestrogens in cardiovascular diseases, cancer, climacteric symptoms and osteoporosis. Drug Saf 24, 665-682.
19. Sirtori CR, Arnoldi A & Johnson SK (2005) Phytoestrogens: end of a tale Ann Med 37, 423-438.
20. Murphy PA, Song T, Buseman G, et al. (1999) Isoflavones in retail and institutional soy foods. J Agric Food Chem 47, 2697-2704.
21. Tham DM, Gardner CD & Haskell WL (1998) Clinical review 97: potential health benefits of dietary phytoestrogens: a review of the clinical, epidemiological, and mechanistic evidence. J Clin Endocrinol Metab 83, 2223-2235.
22. Setchell KD (1985) Naturally occurring, non-steroidal estrogens of dietary origin. In Estrogens in the Environment, pp. 69-86 [J McLachlan, editor]. New York: Elsevier Science Publishing Co.
23. Helferich WG, Andrade JE & Hoagland MS (2008) Phytoestrogens and breast cancer: a complex story. Inflammopharmacology 16, 219-226.
24. Hodges RE, Krehl WA, Stone DB, et al. (1967) Dietary carbohydrates and low cholesterol diets: effects on serum lipids on man. Am J Clin Nutr 20, 198-208.
25. Anderson JW, Johnstone BM & Cook-Newell ME (1995) Meta-analysis of the effects of soy protein intake on serum lipids. N Engl J Med 333, 276-282.
26. Erdman JW Jr (2000) Soy protein and cardiovascular disease: a statement for healthcare professionals from the nutrition committee of the AHA. Circulation 102, 2555-2559.
27. Anonymous (2001) Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285, 2486-2497.
28. Zhan S & Ho SC (2005) Meta-analysis of the effects of soy protein containing isoflavones on the lipid profile. Am J Clin Nutr 81, 397-408.
29. Harland JI & Haffner TA (2008) Systematic review, metaanalysis and regression of randomised controlled trials reporting an association between an intake of circa 25 g soya protein per day and blood cholesterol. Atherosclerosis 200, 13-27.
30. Reynolds K, Chin A, Lees KA, et al. (2006) A meta-analysis of the effect of soy protein supplementation on serum lipids. Am J Cardiol 98, 633-640.
31. Weggemans RM & Trautwein EA (2003) Relation between soy-associated isoflavones and LDL and HDL cholesterol concentrations in humans: a meta-analysis. Eur J Clin Nutr 57, 940-946.
32. Anderson JW & Bush HM (2011) Soy protein effects on serum lipoproteins: a quality assessment and meta-analysis of randomized, controlled studies. J Am Coll Nutr 30, 79-91.
33. Brown L, Rosner B, Willett WW, et al. (1999) Cholesterollowering effects of dietary fiber: a meta-analysis. Am J Clin Nutr 69, 30-42.
34. Messina M (2003) Potential public health implications of the hypocholesterolemic effects of soy protein. Nutrition 19, 280-281.
35. Messina MJ (1999) Legumes and soybeans: overview of their nutritional profiles and health effects. Am J Clin Nutr 70, 439S-450S.
36. Slavin M, Kenworthy W & Yu LL (2009) Antioxidant properties, phytochemical composition, and antiproliferative activity of Maryland-grown soybeans with colored seed coats. J Agric Food Chem 57, 11174-11185.
37. Calder PC (2010) The American Heart Association advisory on n-6 fatty acids: evidence based or biased evidence Br J Nutr 104, 1575-1576.
38. Ramsden CE, Hibbeln JR, Majchrzak SF, et al. (2010) n-6 Fatty acid-specific and mixed polyunsaturate dietary interventions have different effects on CHD risk: a meta-analysis of randomised controlled trials. Br J Nutr 104, 1586-1600.
39. Mozaffarian D, Micha R & Wallace S (2010) Effects on coronary heart disease of increasing polyunsaturated fat in place of saturated fat: a systematic review and meta-analysis of randomized controlled trials. PLoS Med 7, e1000252.
40. Jakobsen MU, O'Reilly EJ, Heitmann BL, et al. (2009) Major types of dietary fat and risk of coronary heart disease: a pooled analysis of 11 cohort studies. Am J Clin Nutr 89, 1425-1432.
41. Astrup A, Dyerberg J, Elwood P, et al. (2011) The role of reducing intakes of saturated fat in the prevention of cardiovascular disease: where does the evidence stand in 2010 Am J Clin Nutr 93, 684-688.
42. Harris WS, Mozaffarian D, Rimm E, et al. (2009) Omega-6 fatty acids and risk for cardiovascular disease: a science advisory from the American Heart Association Nutrition Subcommittee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Cardiovascular Nursing; and Council on Epidemiology and Prevention. Circulation 119, 902-907.
43. Rett BS & Whelan J (2011) Increasing dietary linoleic acid does not increase tissue arachidonic acid content in adults consuming Western-type diets: a systematic review. Nutr Metab (Lond) 8, 36.
44. Calder PC (2009) Polyunsaturated fatty acids and inflammatory processes: new twists in an old tale. Biochimie 91, 791-795.
45. Jenkins DJ, Kendall CW, Faulkner D, et al. (2002) A dietary portfolio approach to cholesterol reduction: combined effects of plant sterols, vegetable proteins, and viscous fibers in hypercholesterolemia. Metabolism 51, 1596-1604.
46. Jenkins DJ, Kendall CW, Marchie A, et al. (2005) Direct comparison of a dietary portfolio of cholesterol-lowering foods with a statin in hypercholesterolemic participants. Am J Clin Nutr 81, 380-387.
47. Law MR, Wald NJ & Thompson SG (1994) By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease BMJ 308, 367-372.
48. Law MR, Wald NJ, Wu T, et al. (1994) Systematic underestimation of association between serum cholesterol concentration and ischaemic heart disease in observational studies: data from the BUPA study. BMJ 308, 363-366.
49. Boden WE (2000) High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High-Density Lipoprotein Intervention Trial. Am J Cardiol 86, 19L-22L.
50. Gotto AM Jr (2002) High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease. Am Heart J 144, S33-S42.
51. Grover SA, Kaouache M, Joseph L, et al. (2009) Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levels. Arch Intern Med 169, 1775-1780.
52. Cullen P (2000) Evidence that triglycerides are an independent coronary heart disease risk factor. Am J Cardiol 86, 943-949.
53. Bansal S, Buring JE, Rifai N, et al. (2007) Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 298, 309-316.
54. Nordestgaard BG, Benn M, Schnohr P, et al. (2007) Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 298, 299-308.
55. Santo AS, Santo AM, Browne RW, et al. (2010) Postprandial lipemia detects the effect of soy protein on cardiovascular disease risk compared with the fasting lipid profile. Lipids 45, 1127-1138.
56. Liu XX, Li SH, Chen JZ, et al. (2012) Effect of soy isoflavones on blood pressure: a meta-analysis of randomized controlled trials. Nutr Metab Cardiovasc Dis 22, 463-470.
57. Hooper L, Kroon PA, Rimm EB, et al. (2008) Flavonoids, flavonoid-rich foods, and cardiovascular risk: a meta-analysis of randomized controlled trials. Am J Clin Nutr 88, 38-50.
58. Taku K, Lin N, Cai D, et al. (2010) Effects of soy isoflavone extract supplements on blood pressure in adult humans: systematic review and meta-analysis of randomized placebo-controlled trials. J Hypertens 28, 1971-1982.
59. McInnes GT (2005) Lowering blood pressure for cardiovascular risk reduction. J Hypertens Suppl 23, S3-S8.
60. Wu J & Muir AD (2008) Isoflavone content and its potential contribution to the antihypertensive activity in soybean Angiotensin I converting enzyme inhibitory peptides. J Agric Food Chem 56, 9899-9904.
61. Yang HY, Yang SC, Chen JR, et al. (2004) Soyabean protein hydrolysate prevents the development of hypertension in spontaneously hypertensive rats. Br J Nutr 92, 507-512.
62. Harada N & Okajima K (2009) Effects of capsaicin and isoflavone on blood pressure and serum levels of insulinlike growth factor-I in normotensive and hypertensive volunteers with alopecia. Biosci Biotechnol Biochem 73, 1456-1459.
63. Bitto A, Altavilla D, Bonaiuto A, et al. (2009) Effects of aglycone genistein in a rat experimental model of postmenopausal metabolic syndrome. J Endocrinol 200, 367-376.
64. Nestel PJ, Yamashita T, Sasahara T, et al. (1997) Soy isoflavones improve systemic arterial compliance but not plasma lipids in menopausal and perimenopausal women. Arterioscler Thromb Vasc Biol 17, 3392-3398.
65. Hoshida S, Miki T, Nakagawa T, et al. (2011) Different effects of isoflavones on vascular function in premenopausal and postmenopausal smokers and nonsmokers: NYMPH study. Heart Vessels 26, 590-595.
66. Gardner-Thorpe D, O'Hagen C, Young I, et al. (2003) Dietary supplements of soya flour lower serum testosterone concentrations and improve markers of oxidative stress in men. Eur J Clin Nutr 57, 100-106.
67. Allen JK, Becker DM, Kwiterovich PO, et al. (2007) Effect of soy protein-containing isoflavones on lipoproteins in postmenopausal women. Menopause 14, 106-114.
68. Desroches S, Mauger JF, Ausman LM, et al. (2004) Soy protein favorably affects LDL size independently of isoflavones in hypercholesterolemic men and women. J Nutr 134, 574-579.
69. Bonetti PO, Lerman LO & Lerman A (2003) Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 23, 168-175.
70. Beavers DP, Beavers KM, Miller M, et al. (2012) Exposure to isoflavone-containing soy products and endothelial function: a Bayesian meta-analysis of randomized controlled trials. Nutr Metab Cardiovasc Dis 22, 182-91.
71. Squadrito F, Altavilla D, Squadrito G, et al. (2000) Genistein supplementation and estrogen replacement therapy improve endothelial dysfunction induced by ovariectomy in rats. Cardiovasc Res 45, 454-462.
72. Chan YH, Lam TH, Lau KK, et al. (2011) Dietary intake of phytoestrogen is associated with increased circulating endothelial progenitor cells in patients with cardiovascular disease. Eur J Cardiovasc Prev Rehabil 18, 360-368.
73. Hoshida S, Miki T, Nakagawa T, et al. (2011) Different effects of isoflavones on vascular function in premenopausal and postmenopausal smokers and nonsmokers: NYMPH study. Heart Vessels 26, 590-595.
74. Hodis HN, Mack WJ, Kono N, et al. (2011) Isoflavone soy protein supplementation and atherosclerosis progression in healthy postmenopausal women: a randomized controlled trial. Stroke 42, 3168-3175.
75. Hodis HN & Mack WJ (2011) A "window of opportunity:" the reduction of coronary heart disease and total mortality with menopausal therapies is age-and time-dependent. Brain Res 1379, 244-252.
76. Sherwin BB (2007) The critical period hypothesis: can it explain discrepancies in the oestrogen-cognition literature J Neuroendocrinol 19, 77-81.
77. Ju YH, Fultz J, Allred KF, et al. (2006) Effects of dietary daidzein and its metabolite, equol, at physiological concentrations on the growth of estrogen-dependent human breast cancer (MCF-7) tumors implanted in ovariectomized athymic mice. Carcinogenesis 27, 856-863.
78. Ju YH, Doerge DR, Allred KF, et al. (2002) Dietary genistein negates the inhibitory effect of tamoxifen on growth of estrogen-dependent human breast cancer (MCF-7) cells implanted in athymic mice. Cancer Res 62, 2474-2477.
79. Ju YH, Doerge DR, Woodling KA, et al. (2008) Dietary genistein negates the inhibitory effect of letrozole on the growth of aromatase-expressing estrogen-dependent human breast cancer cells (MCF-7Ca) in vivo. Carcinogenesis 29, 2162-2168.
80. Onoda A, Ueno T, Uchiyama S, et al. (2011) Effects of S-equol and natural S-equol supplement (SE5-OH) on the growth of MCF-7 in vitro and as tumors implanted into ovariectomized athymic mice. Food Chem Toxicol 49, 2279-2284.
81. Setchell KD, Brown NM, Zhao X, et al. (2011) Soy isoflavone phase II metabolism differs between rodents and humans: implications for the effect on breast cancer risk. Am J Clin Nutr 94, 1284-1294.
82. Murphy PA, Barua K & Hauck CC (2002) Solvent extraction selection in the determination of isoflavones in soy foods. J Chromatogr B Analyt Technol Biomed Life Sci 777, 129-138.
83. Messina M, Nagata C & Wu AH (2006) Estimated Asian adult soy protein and isoflavone intakes. Nutr Cancer 55, 1-12.
84. Oseni T, Patel R, Pyle J, et al. (2008) Selective estrogen receptor modulators and phytoestrogens. Planta Med 74, 1656-1665.
85. Pike AC (2006) Lessons learnt from structural studies of the oestrogen receptor. Best Pract Res Clin Endocrinol Metab 20, 1-14.
86. Reiter E, Beck V, Medjakovic S, et al. (2009) Isoflavones are safe compounds for therapeutical applications-evaluation of in vitro data. Gynecol Endocrinol 25, 554-580.
87. Speirs V, Carder PJ, Lane S, et al. (2004) Oestrogen receptor beta: what it means for patients with breast cancer. Lancet Oncol 5, 174-181.
88. Carmignani LO, Pedro AO, Costa-Paiva LH, et al. (2010) The effect of dietary soy supplementation compared to estrogen and placebo on menopausal symptoms: a randomized controlled trial. Maturitas 67, 262-269.
89. Bondesson M & Gustafsson JA (2010) Does consuming isoflavones reduce or increase breast cancer risk Genome Med 2, 90.
90. Penttinen-Damdimopoulou PE, Power KA, Hurmerinta TT, et al. (2009) Dietary sources of lignans and isoflavones modulate responses to estradiol in estrogen reporter mice. Mol Nutr Food Res 53, 996-1006.
91. Pasqualini JR, Chetrite G, Blacker C, et al. (1996) Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre-and postmenopausal breast cancer patients. J Clin Endocrinol Metab 81, 1460-1464.
92. Geisler J (2003) Breast cancer tissue estrogens and their manipulation with aromatase inhibitors and inactivators. J Steroid Biochem Mol Biol 86, 245-253.
93. Haynes BP, Straume AH, Geisler J, et al. (2010) Intratumoral estrogen disposition in breast cancer. Clin Cancer Res 16, 1790-1801.
94. Writing Group for the Women's Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288, 321-333.
95. Chlebowski RT, Anderson GL, Gass M, et al. (2010) Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 304, 1684-1692.
96. Anderson GL, Limacher M, Assaf AR, et al. (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291, 1701-1712.
97. Stefanick ML, Anderson GL, Margolis KL, et al. (2006) Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 295, 1647-1657.
98. LaCroix AZ, Chlebowski RT, Manson JE, et al. (2011) Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 305, 1305-1314.
99. Anderson GL, Chlebowski RT, Aragaki AK, et al. (2012) Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol 13, 476-486.
100. Warren MP (2004) A comparative review of the risks and benefits of hormone replacement therapy regimens. Am J Obstet Gynecol 190, 1141-1167.
101. Ross RK, Paganini-Hill A, Wan PC, et al. (2000) Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 92, 328-332.
102. Schairer C, Lubin J, Troisi R, et al. (2000) Estrogen-progestin replacement and risk of breast cancer. JAMA 284, 691-694.
103. Li CI, Malone KE, Porter PL, et al. (2003) Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA 289, 3254-3263.
104. Chen WY, Manson JE, Hankinson SE, et al. (2006) Unopposed estrogen therapy and the risk of invasive breast cancer. Arch Intern Med 166, 1027-1032.
105. Greendale GA, Reboussin BA, Slone S, et al. (2003) Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst 95, 30-37.
106. Hofseth LJ, Raafat AM, Osuch JR, et al. (1999) Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab 84, 4559-4565.
107. Conner P, Skoog L & Soderqvist G (2001) Breast epithelial proliferation in postmenopausal women evaluated through fine-needle-aspiration cytology. Climacteric 4, 7-12.
108. Conner P, Soderqvist G, Skoog L, et al. (2003) Breast cell proliferation in postmenopausal women during HRT evaluated through fine needle aspiration cytology. Breast Cancer Res Treat 78, 159-165.
109. Messina MJ & Wood CE (2008) Soy isoflavones, estrogen therapy, and breast cancer risk: analysis and commentary. Nutr J 7, 17.
110. Boyd NF, Martin LJ, Li Q, et al. (2006) Mammographic density as a surrogate marker for the effects of hormone therapy on risk of breast cancer. Cancer Epidemiol Biomarkers Prev 15, 961-966.
111. Boyd NF, Lockwood GA, Martin LJ, et al. (2001) Mammographic density as a marker of susceptibility to breast cancer: a hypothesis. IARC Sci Publ 154, 163-169.
112. Conner P (2007) Breast response to menopausal hormone therapy-aspects on proliferation, apoptosis and mammographic density. Ann Med 39, 28-41.
113. Hooper L, Ryder JJ, Kurzer MS, et al. (2009) Effects of soy protein and isoflavones on circulating hormone concentrations in pre-and post-menopausal women: a systematic review and meta-analysis. Hum Reprod Update 15, 423-440.
114. Huber J, Imhof M & Schmidt M (2010) Effects of soy protein and isoflavones on circulating hormone concentrations in pre-and post-menopausal women: a systematic review and meta-analysis. Hum Reprod Update 16, 110-111 (author reply 1-2).
115. Khan SA, Chatterton RT, Michel N, et al. (2012) Soy isoflavone supplementation for breast cancer risk reduction: a randomized phase II trial. Cancer Prev Res (Phila) 5, 309-319.
116. Murkes D, Conner P, Leifland K, et al. (2011) Effects of percutaneous estradiol-oral progesterone versus oral conjugated equine estrogens- medroxyprogesterone acetate on breast cell proliferation and bcl-2 protein in healthy women. Fertil Steril 95, 1188-1191.
117. Messina M & Barnes S (1991) The role of soy products in reducing risk of cancer. J Natl Cancer Inst 83, 541-546.
118. Adlercreutz H (1988) Lignans and phytoestrogens. Possible preventive role in cancer. Front Gastrointest Res 14, 165-176.
119. Setchell KD, Borriello SP, Hulme P, et al. (1984) Nonsteroidal estrogens of dietary origin: possible roles in hormonedependent disease. Am J Clin Nutr 40, 569-578.
120. Boyapati SM, Shu XO, Ruan ZX, et al. (2005) Soyfood intake and breast cancer survival: a followup of the Shanghai Breast Cancer Study. Breast Cancer Res Treat 92, 11-17.
121. Shu XO, Zheng Y, Cai H, et al. (2009) Soy food intake and breast cancer survival. JAMA 302, 2437-2443.
122. Kang HJ, Ansbacher R & Hammoud MM (2002) Use of alternative and complementary medicine in menopause. Int J Gynaecol Obstet 79, 195-207.
123. Guha N, Kwan ML, Quesenberry CP, et al. (2009) Soy isoflavones and risk of cancer recurrence in a cohort of breast cancer survivors: the Life After Cancer Epidemiology study. Breast Cancer Res Treat 118, 395-405.
124. Caan BJ, Natarajan L, Parker B, et al. (2011) Soy food consumption and breast cancer prognosis. Cancer Epidemiol Biomarkers Prev 20, 854-858.
125. Woo HD, Park KS, Ro J, et al. (2012) Differential influence of dietary soy intake on the risk of breast cancer recurrence related to HER2 status. Nutr Cancer 64, 198-205.
126. Kang X, Zhang Q, Wang S, et al. (2010) Effect of soy isoflavones on breast cancer recurrence and death for patients receiving adjuvant endocrine therapy. CMAJ 182, 1857-1862.
127. Hilakivi-Clarke L, Andrade JE & Helferich W (2010) Is soy consumption good or bad for the breast J Nutr 140, 2326S-2334S.
128. Hicks DG & Kulkarni S (2008) HER2\+ breast cancer: review of biologic relevance and optimal use of diagnostic tools. Am J Clin Pathol 129, 263-273.
129. Dong JY, Tong X, Wu ZW, et al. (2011) Effect of soya protein on blood pressure: a meta-analysis of randomised controlled trials. Br J Nutr 106, 317-326.
130. Hodis HN, Mack WJ, Kono N, et al. (2011) Isoflavone soy protein supplementation and atherosclerosis progression in healthy postmenopausal women: a randomized controlled trial. Stroke 42, 3168-3175.
131. Caan BJ, Natarajan L, Parker BA, et al. (2011) Soy food consumption and breast cancer prognosis. Cancer Epidemiol Biomarkers Prev 20, 854-858.